 Paul Kent
Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 12 | 2021 | 121 | 4.090 |
Why?
| | Sarcoma | 9 | 2020 | 139 | 3.140 |
Why?
| | Osteosarcoma | 8 | 2021 | 42 | 2.220 |
Why?
| | Soft Tissue Neoplasms | 2 | 2021 | 53 | 1.350 |
Why?
| | Child | 14 | 2021 | 1572 | 1.140 |
Why?
| | Antineoplastic Agents | 3 | 2015 | 274 | 0.980 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2021 | 405 | 0.960 |
Why?
| | Child, Preschool | 11 | 2020 | 786 | 0.940 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2021 | 236 | 0.930 |
Why?
| | Adolescent | 12 | 2021 | 2667 | 0.920 |
Why?
| | Salvage Therapy | 1 | 2021 | 42 | 0.840 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 34 | 0.840 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2021 | 41 | 0.840 |
Why?
| | Adenoviridae Infections | 1 | 2020 | 3 | 0.830 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 76 | 0.810 |
Why?
| | Coinfection | 1 | 2020 | 33 | 0.800 |
Why?
| | Thoracic Vertebrae | 1 | 2021 | 117 | 0.760 |
Why?
| | Young Adult | 12 | 2021 | 2277 | 0.760 |
Why?
| | Positron-Emission Tomography | 1 | 2020 | 95 | 0.760 |
Why?
| | Brain Neoplasms | 1 | 2021 | 187 | 0.750 |
Why?
| | Mandibular Neoplasms | 1 | 2019 | 3 | 0.750 |
Why?
| | Sickle Cell Trait | 1 | 2018 | 5 | 0.720 |
Why?
| | Television | 1 | 2018 | 9 | 0.720 |
Why?
| | Neoadjuvant Therapy | 1 | 2019 | 71 | 0.710 |
Why?
| | Information Dissemination | 1 | 2018 | 21 | 0.710 |
Why?
| | Coronavirus Infections | 1 | 2020 | 97 | 0.690 |
Why?
| | Genetic Testing | 1 | 2018 | 73 | 0.690 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 102 | 0.690 |
Why?
| | Sports Medicine | 1 | 2018 | 42 | 0.690 |
Why?
| | Social Media | 1 | 2018 | 35 | 0.670 |
Why?
| | Athletes | 1 | 2018 | 77 | 0.670 |
Why?
| | Tomography, X-Ray Computed | 3 | 2020 | 891 | 0.670 |
Why?
| | Neoplasm Staging | 3 | 2016 | 481 | 0.660 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2021 | 300 | 0.640 |
Why?
| | Algorithms | 1 | 2019 | 412 | 0.600 |
Why?
| | Treatment Refusal | 1 | 2015 | 13 | 0.580 |
Why?
| | Humans | 25 | 2021 | 31481 | 0.570 |
Why?
| | Medical Oncology | 1 | 2015 | 39 | 0.560 |
Why?
| | Lung | 1 | 2015 | 171 | 0.540 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2014 | 7 | 0.530 |
Why?
| | Infant | 4 | 2020 | 642 | 0.520 |
Why?
| | Limb Salvage | 1 | 2013 | 10 | 0.510 |
Why?
| | Chordoma | 1 | 2013 | 10 | 0.510 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 181 | 0.510 |
Why?
| | Prognosis | 5 | 2021 | 1028 | 0.500 |
Why?
| | Postoperative Complications | 1 | 2021 | 1083 | 0.500 |
Why?
| | Torsades de Pointes | 1 | 2013 | 11 | 0.500 |
Why?
| | Paraneoplastic Syndromes | 1 | 2013 | 9 | 0.490 |
Why?
| | Long QT Syndrome | 1 | 2013 | 14 | 0.490 |
Why?
| | Membrane Proteins | 1 | 2014 | 230 | 0.460 |
Why?
| | Male | 13 | 2021 | 17583 | 0.460 |
Why?
| | Neoplasms | 1 | 2015 | 280 | 0.460 |
Why?
| | Liver Neoplasms | 1 | 2013 | 117 | 0.440 |
Why?
| | Adult | 12 | 2021 | 9779 | 0.430 |
Why?
| | Bone Transplantation | 1 | 2013 | 231 | 0.420 |
Why?
| | Lung Neoplasms | 2 | 2015 | 756 | 0.390 |
Why?
| | Female | 10 | 2021 | 18253 | 0.350 |
Why?
| | Retrospective Studies | 5 | 2021 | 3591 | 0.320 |
Why?
| | Sarcoma, Ewing | 3 | 2013 | 9 | 0.280 |
Why?
| | Chondrosarcoma | 3 | 2013 | 40 | 0.280 |
Why?
| | Anticoagulants | 2 | 2005 | 151 | 0.280 |
Why?
| | Survival Rate | 2 | 2021 | 465 | 0.230 |
Why?
| | Interferons | 1 | 2021 | 15 | 0.220 |
Why?
| | Follow-Up Studies | 4 | 2021 | 2028 | 0.220 |
Why?
| | Fluorouracil | 1 | 2021 | 88 | 0.210 |
Why?
| | Illinois | 1 | 2021 | 266 | 0.200 |
Why?
| | Minority Health | 1 | 2019 | 3 | 0.200 |
Why?
| | Education, Medical, Undergraduate | 1 | 2019 | 37 | 0.190 |
Why?
| | Attitude to Health | 1 | 2019 | 117 | 0.180 |
Why?
| | United States | 2 | 2018 | 2539 | 0.180 |
Why?
| | Curriculum | 1 | 2019 | 158 | 0.180 |
Why?
| | Pandemics | 1 | 2020 | 203 | 0.170 |
Why?
| | Clinical Competence | 1 | 2019 | 274 | 0.160 |
Why?
| | Gingivitis, Necrotizing Ulcerative | 1 | 2015 | 2 | 0.150 |
Why?
| | Disease-Free Survival | 1 | 2015 | 241 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 230 | 0.140 |
Why?
| | Pediatrics | 1 | 2015 | 48 | 0.140 |
Why?
| | Data Collection | 1 | 2015 | 120 | 0.140 |
Why?
| | Nurses | 1 | 2015 | 51 | 0.140 |
Why?
| | Risk Factors | 2 | 2020 | 2664 | 0.140 |
Why?
| | Heart Neoplasms | 1 | 2014 | 21 | 0.130 |
Why?
| | Combined Modality Therapy | 2 | 2013 | 456 | 0.130 |
Why?
| | Physicians | 1 | 2015 | 120 | 0.130 |
Why?
| | Interdisciplinary Communication | 1 | 2013 | 31 | 0.130 |
Why?
| | Radiation Dosage | 1 | 2013 | 35 | 0.130 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2013 | 30 | 0.120 |
Why?
| | Emergencies | 1 | 2013 | 41 | 0.120 |
Why?
| | Survival Analysis | 1 | 2013 | 379 | 0.120 |
Why?
| | Biomedical Research | 1 | 2013 | 89 | 0.120 |
Why?
| | Allografts | 1 | 2013 | 171 | 0.110 |
Why?
| | Fetal Diseases | 1 | 2011 | 10 | 0.110 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2011 | 9 | 0.110 |
Why?
| | Cranial Sinuses | 1 | 2011 | 9 | 0.110 |
Why?
| | Prenatal Diagnosis | 1 | 2011 | 21 | 0.110 |
Why?
| | Prostheses and Implants | 1 | 2013 | 166 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2013 | 378 | 0.110 |
Why?
| | Femur | 1 | 2014 | 389 | 0.100 |
Why?
| | Incidence | 1 | 2013 | 829 | 0.100 |
Why?
| | Superior Vena Cava Syndrome | 1 | 2005 | 8 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 1273 | 0.070 |
Why?
| | Drug Delivery Systems | 1 | 2005 | 40 | 0.070 |
Why?
| | Tissue Plasminogen Activator | 1 | 2005 | 80 | 0.070 |
Why?
| | Thrombolytic Therapy | 1 | 2005 | 85 | 0.070 |
Why?
| | Thrombosis | 1 | 2005 | 67 | 0.070 |
Why?
| | Fibrinolytic Agents | 1 | 2005 | 99 | 0.070 |
Why?
| | Diagnosis, Differential | 2 | 2015 | 467 | 0.060 |
Why?
| | Middle Aged | 1 | 2015 | 11209 | 0.050 |
Why?
| | Sex Reassignment Procedures | 1 | 2019 | 2 | 0.050 |
Why?
| | Hormones | 1 | 2019 | 19 | 0.050 |
Why?
| | Culturally Competent Care | 1 | 2019 | 10 | 0.050 |
Why?
| | Cultural Competency | 1 | 2019 | 15 | 0.050 |
Why?
| | Healthcare Disparities | 1 | 2019 | 82 | 0.050 |
Why?
| | Mental Health | 1 | 2019 | 119 | 0.040 |
Why?
| | Taxoids | 1 | 2016 | 16 | 0.040 |
Why?
| | Deoxycytidine | 1 | 2016 | 43 | 0.040 |
Why?
| | Immunocompromised Host | 1 | 2015 | 55 | 0.040 |
Why?
| | Hemorrhage | 1 | 2015 | 90 | 0.040 |
Why?
| | Ventricular Septum | 1 | 2014 | 4 | 0.030 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2014 | 13 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2014 | 75 | 0.030 |
Why?
| | Metastasectomy | 1 | 2013 | 7 | 0.030 |
Why?
| | Cancer Vaccines | 1 | 2013 | 20 | 0.030 |
Why?
| | Angiogenesis Inhibitors | 1 | 2013 | 24 | 0.030 |
Why?
| | Receptor, IGF Type 1 | 1 | 2013 | 21 | 0.030 |
Why?
| | Biopsy | 1 | 2014 | 283 | 0.030 |
Why?
| | Echocardiography | 1 | 2014 | 197 | 0.030 |
Why?
| | Lymphoma | 1 | 2013 | 56 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 39 | 0.030 |
Why?
| | Immunotherapy | 1 | 2013 | 74 | 0.030 |
Why?
| | Meglumine | 1 | 2011 | 4 | 0.030 |
Why?
| | Organometallic Compounds | 1 | 2011 | 23 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 301 | 0.030 |
Why?
| | Gestational Age | 1 | 2011 | 100 | 0.030 |
Why?
| | Contrast Media | 1 | 2011 | 144 | 0.030 |
Why?
| | Pregnancy | 1 | 2011 | 457 | 0.030 |
Why?
| | Platelet Transfusion | 1 | 2005 | 7 | 0.020 |
Why?
| | Enoxaparin | 1 | 2005 | 9 | 0.020 |
Why?
| | Escherichia coli Infections | 1 | 2005 | 32 | 0.020 |
Why?
| | Catheterization, Peripheral | 1 | 2005 | 18 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2015 | 3910 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2005 | 89 | 0.020 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 40 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2005 | 265 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2005 | 295 | 0.020 |
Why?
| | Bacteremia | 1 | 2005 | 122 | 0.020 |
Why?
| | Ultrasonography | 1 | 2005 | 210 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2005 | 412 | 0.010 |
Why?
|
|
Kent's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|